0001654954-24-006744.txt : 20240521 0001654954-24-006744.hdr.sgml : 20240521 20240521170050 ACCESSION NUMBER: 0001654954-24-006744 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240517 FILED AS OF DATE: 20240521 DATE AS OF CHANGE: 20240521 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Giordano Christopher Thomas CENTRAL INDEX KEY: 0001871714 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-34600 FILM NUMBER: 24970392 MAIL ADDRESS: STREET 1: C/O TENAX THERAPEUTICS, INC. STREET 2: ONE COPLEY PARKWAY, SUITE 490 CITY: MORRISVILLE STATE: NC ZIP: 27560 FORMER NAME: FORMER CONFORMED NAME: Giordano Chrisopher Thomas DATE OF NAME CHANGE: 20210708 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: TENAX THERAPEUTICS, INC. CENTRAL INDEX KEY: 0000034956 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 262593535 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 101 GLEN LENNOX DRIVE STREET 2: SUITE 300 CITY: CHAPEL HILL STATE: NC ZIP: 27517 BUSINESS PHONE: 919-855-2100 MAIL ADDRESS: STREET 1: 101 GLEN LENNOX DRIVE STREET 2: SUITE 300 CITY: CHAPEL HILL STATE: NC ZIP: 27517 FORMER COMPANY: FORMER CONFORMED NAME: OXYGEN BIOTHERAPEUTICS, INC. DATE OF NAME CHANGE: 20080703 FORMER COMPANY: FORMER CONFORMED NAME: SYNTHETIC BLOOD INTERNATIONAL INC DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: SINEQUANON CORP DATE OF NAME CHANGE: 19901219 4 1 section16.xml PRIMARY DOCUMENT X0508 4 2024-05-17 0000034956 TENAX THERAPEUTICS, INC. TENX 0001871714 Giordano Christopher Thomas 101 GLEN LENNOX DRIVE. SUITE 300 CHAPEL HILL NC 27517 true true CEO false Stock Option (right to buy) 3.549 2024-05-17 4 A false 437 0.00 A 2034-05-17 Common Stock 437 437 D Stock Option (right to buy) 992 2032-06-09 Common Stock 125 125 D Stock Option (right to buy) 3152 2031-07-06 Common Stock 157 157 D The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on each of May 17, 2025, May 17, 2026, May 17, 2027, and May 17, 2028, subject to the Reporting Person's continued employment. These options were previously reported as covering 200,000 shares at an exercise price of $0.62 per share, but were adjusted to reflect the stock splits that occurred on January 4, 2023 and January 2, 2024. The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on each of June 9, 2023, June 9, 2024, June 9, 2025, and June 9, 2026, subject to the Reporting Person's continued employment. These options were previously reported as covering 250,000 shares at an exercise price of $1.97 per share, but were adjusted to reflect the stock splits that occurred on January 4, 2023 and January 2, 2024. The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on each of July 6, 2022, July 6, 2023, July 6, 2024, and July 6, 2025, subject to the Reporting Person's continued employment. /s/ S. Halle Vakani, as Attorney-in-Fact 2024-05-21